Skip to main content
. 2012 Jul 2;2012:946943. doi: 10.1155/2012/946943

Table 1.

Synergistic effects between PPARγ ligands and other agents in vitro. Descriptions reflect most noteworthy finding of each study.

Platinum-Based Compounds Taxanes Topoisomerase Inhibitors Anti-metabolites RXRα ligands Cell Signalling Molecules Statins
Rosiglitazone (i) ↓ Cell growth in A549, Calu1, H23, H596 and H1650 NSCLC; Mosher colon; and OVCA420, OVCA429 and ES2 ovarian cancer [31] (i) ↓ Cell viability in BEL-7402 and Huh-7 Hepatocellular carcinoma [37] (i) ↑ Differentiating and growth-inhibitory effects in lymphoid Su-DHL, Sup-M2, Ramos, Raji, Hodgkin's cell lines, and primary chronic lymphocytic (lymphoid), and U937 and HL-60 (myeloid) leukemia [38] (i) ↑ Growth inhibition in MDA- MB-231 breast cancer [39] *pre-treatment
(ii) ↑ Apoptosis in HT-29 colon cancer [40] (ii) ↓ Cell viability in MCF-7, MCF-7TR1, SKBR-3, and T-47D breast cancer [41]

Troglitazone (i) ↑ Growth inhibition in A549 and H522 NSCLC [33] *post-treatment (i) ↑ Growth inhibition in A549 and H522 NSCLC [33] *post-treatment (i) ↑ Growth inhibition in MCF-7, T-47D, ZR-75-1 breast cancer [42] (i) ↓ Cell numbers in HEY ovarian cancer [43]
(ii) ↑ Growth inhibition in EHMES-10 mesothelioma [34] (ii) ↑ Apoptosis in MCF-7, SKBR-3, and MDA-MB-453 breast cancer [44]

Pioglitazone (i) ↑ Growth inhibition in A549 and H522 NSCLC [33] *post-treatment (i) ↑ Differentiation in harvested liposarcoma cells [45] (i) Cytotoxic effects in U87, U138, LN 405 and rat RG II glioblastoma [46]
(ii) ↑ Cytotoxic effects in IOMM Lee and KT21-MG1 meningioma [47]

Ciglitazone (i) ↑ Growth inhibition in ZR-75-1 and T-47D breast; and Calu-6 lung cancer [48] (i) ↓ Proliferation in HEY ovarian cancer [43] (i) ↑ Cytotoxic and cytostatic effects in Panc 02 and MIA PaCa-2 pancreatic; C-26 colon; and EMT6 and MDA-MB-361 breast cancer [49]
(ii) Apoptosis in ANBL6 and 8226 multiple myeloma [50]; C6, U87MG andGL261 glioblastoma [51],and G361 melanoma [50, 52]

RS5444 (i) ↑ Antiproliferative effects in DRO90-1 and ARO81 anaplastic thyroid carcinoma [53]

15d-PGJ2 (i) ↑ Cytotoxicity in A549 and H460 NSCLC [54] (i) ↑ Cytotoxicity in Cak-2 renal cell carcinoma [55] (i) ↑ Differentiating and growth-inhibitory effects in Su-DHL, Sup-M2, Ramos, Raji, Hodgkin's cell lines, and primary chronic lymphocytic (lymphoid), and U937 and HL-60 (myeloid) leukemia [38] (i) ↑ Growth inhibition in HEY ovarian cancer [43]
(ii) ↑ Apoptosis in ANBL6 and 8226 multiple myeloma [51]

LY 293111 (i) ↑ Cytotoxicity in MCF-7, MCF-7/adr and SKBR-3 breast; H460 lung; SW480 and RT4 colon; and HT1197 bladder cancer [6]

Linoleic Acid (i) ↑ Apoptosis and ↓ proliferation in MCF-7, MDA-MB-231, MDA-MB-468, T-47D and SKBR-3 breast cancer [56]